South Korean medical AI developer Deep Bio is rolling out its software to aid in prostate cancer diagnosis to five local hospitals as part of a recently signed trial purchase agreement.
The AI product will be tested at SMG-SNU Boramae Medical Center, Chungnam National University Sejong Hospital, Korea Institute of Radiological & Medical Sciences, Jeju National University Hospital and Changwon Hospital under Gyeongsang National University.
WHAT IT’S ABOUT
The trial purchase comes before the full integration of DeepDx Prostate Pro by Deep Bio into hospital pathology workflows in November. It is used to assist pathologists in determining the extent of the disease. tumor severity, confirm the diagnosis and study.
Medical software based on deep learning analyzes the entire slide image of a prostate needle biopsy and automatically classifies the severity of prostate cancer. Based on evaluation studies, this tool shows 98.7% concordance in class group classification and 96.9% concordance in group classification “no class” compared to the reference standard due to three pathologist created.
TREND TO BIGGER WOMAN
In November last year, Deep Bio received approval from the Department of Food and Drug Safety for DeepDx Prostate Pro. In July of this year, the software was designated as an innovative product by Korean regulatory authorities.
The technology is currently being worked on by researchers at Stanford University School of Medicine, which recently renewed a software licensing contract with the company.
DeepDx Prostate is also being used by Morphle Labs pathologists in India and the US. It is also being distributed throughout Switzerland and North Africa through Deep Bio’s partnership with Swiss medical device distributor HealthCare Konnect.
ON PROFILE
In a press statement, CEO Sun-Woo Kim said “through this pilot purchase project, Deep Bio will lead the introduction of digital pathology in Korea as well as accelerate the expansion of domestic market.”
He added: “We very much look forward to demonstrating that our software can be seamlessly integrated into existing pathology processes, bringing about positive changes such as reducing the doctor’s workload. pathologists and improve efficiency in real medical settings.
